Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Wegovy and Zepbound belong to the same class of medications, known as GLP-1s, but they work in slightly different ways. In a recent head-to-head study, Zepbound was shown to be more effective than ...

In interviews, patients said that they had specifically sought out Zepbound and didn’t want to switch. “I chose Zepbound with my doctor,” said Carl Houde, 49, of Saugus, Mass.

If you want to continue GLP-1 therapy, you’ll likely need to switch to a brand-name GLP-1. Examples of these include semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound).

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

While Zepbound leads today, the next potential rally may be sparked by Orforglipron, Eli Lilly's small-molecule oral GLP-1. Phase 3 obesity data is expected in the third quarter, with a launch ...

Nearly twice as many patients on Zepbound lost at least 25% of their body weight as those on Wegovy. Additionally, 81.6% of Zepbound patients lost 10% or more, versus 60.5% of those on Wegovy.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.